Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
List view / Grid view
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.